An observational study in Bilateral Cataract and Presbyopia, sponsored by Center For Sight. Completed at 2 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-03-18.
Sponsored by Center For Sight · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.
Among the 456 studies in Cataract with a site in United States, this one is the 83rd largest by enrollment of the 128 observational ones that give a count, is one of 28 that started in 2022, is one of 128 observational ones, and was the 351st registered.
1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.
Browse Cataract studies →49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eric Rosenberg · Sites in United States
Ages 18–90
The Eye Institute of West Florida · Sites in United States
Ages 40+
Gainesville Eye Associates · Sites in United States
Ages 18+
Laser Defined Vision · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
456 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 25 · Phase 3 59 · Phase 4 86
First in 1987; this study’s year is marked. 28 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 90 across 477 observational studies indexed under Cataract.
Median enrollment 100 across the 322 interventional studies, 61 across the 128 observational. Of the 365 that completed or were terminated, 177 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
239 of 456 have an industry lead sponsor. The 10 most frequent:
Center For Sight is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Center For Sight has 2 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
21 of the studies in Cataract with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07898917Gainesville Eye AssociatesPureSee/Odyssey Mix-and-Match IOL | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
| NCT07260695Center For SightOdyssey Evaluation in Post LASIK Patients | 2026-12-18 |
| NCT03713268Duke UniversityIntraoperative OCT Guidance of Intraocular Surgery II | 2026-12-31 |
| NCT07715591University of California, Los AngelesRandomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention During Awake Cataract Surgery | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 456 studies in Cataract with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Current visual outcomes expectations of cataract patients are similar to those of refractive surgery patients. Their desire is to be spectacle independent for far, intermediate and near vision activities. Some may have already enjoyed freedom from glasses and would like to continue after the cataracts are removed. Different options are available. These options include: mono-vision and presbyopia correcting intraocular lenses (IOL). Presbyopia correcting IOLs include accommodative, multifocals and extended depth of focus (EDOF) IOLs. In a previous study that evaluated the visual outcomes of an EDOF IOL when combined with a multifocal IOL with a +3.25 D add in patients with or without astigmatism undergoing routine cataract surgery showed good outcomes with high patient satisfaction and less dependance on glasses for intermediate and near activities. As technology evolves, new lens models are available in the market. The purpose of this study is to evaluate the latest EDOF and a hybrid multifocal lenses when combined.
Patients from two ophthalmology clinics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Symfony & Synergy IOL combination
The Symfony IOL will be implanted in the dominant eye while the Synergy IOL will be implanted in the non-dominant eye.
Binocular Defocus Curve
Time frame: 3 months
Patient Satisfaction Questionnaire
Percentage for participants who are completely or mostly satisfied with their overall vision will be assessed
Time frame: 3 months
Spectacle Independence for Near Activities Questionnaire
Percentage of participants reporting the need to wear glasses all the time for near activities will be assessed.
Time frame: 3 months
| Milestone | Symfony & Synergy IOL Combination |
|---|---|
| Started | 41 |
| Completed | 37 |
| Not completed | 4 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Adverse event | 1 |
| logMAR | Symfony & Synergy IOL Combination |
|---|---|
| +1.00 D | 0.07 ± 0.10 |
| +0.50 D | -0.05 ± 0.08 |
| 0.00 D | -0.08 ± 0.12 |
| -0.50 D | -0.05 ± 0.09 |
| -1.00 D | -0.04 ± 0.10 |
| -1.50 D | -0.03 ± 0.13 |
| -2.00 D | 0.04 ± 0.13 |
| -2.50 D | 0.07 ± 0.14 |
| -3.00 D | 0.14 ± 0.14 |
Percentage for participants who are completely or mostly satisfied with their overall vision will be assessed
| Participants | Symfony & Synergy IOL Combination |
|---|---|
| Patient Satisfaction Questionnaire | 31 |
Percentage of participants reporting the need to wear glasses all the time for near activities will be assessed.
| Participants | Symfony & Synergy IOL Combination |
|---|---|
| Spectacle Independence for Near Activities Questionnaire | 4 |
Collected over 3 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Symfony & Synergy IOL Combination | 0/37 (0%) | 0/37 (0%) | 0/37 (0%) |
| Age, Continuous(years) | Symfony & Synergy IOL Combination |
|---|---|
| Mean | 68.6 ± 6.3 |
| Sex: Female, Male(Participants) | Symfony & Synergy IOL Combination |
|---|---|
| Female | 27 |
| Male | 10 |
| Race (NIH/OMB)(Participants) | Symfony & Synergy IOL Combination |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 37 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Symfony & Synergy IOL Combination |
|---|---|
| United States | 37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in May 2023, 6 months.
Results were first posted in Mar 2024, 10 months after primary completion.
Of 169 non-industry observational studies under Cataract, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 30. This study's 6 months is below that.
Counting every sponsor, half of 236 studies reached it within 16 months; a quarter within 9 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Center For Sight